AU750660B2 - Method of detecting cancerous lesions - Google Patents

Method of detecting cancerous lesions Download PDF

Info

Publication number
AU750660B2
AU750660B2 AU57884/01A AU5788401A AU750660B2 AU 750660 B2 AU750660 B2 AU 750660B2 AU 57884/01 A AU57884/01 A AU 57884/01A AU 5788401 A AU5788401 A AU 5788401A AU 750660 B2 AU750660 B2 AU 750660B2
Authority
AU
Australia
Prior art keywords
subareas
value
skin
cluster
predetermined area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU57884/01A
Other versions
AU5788401A (en
Inventor
Michael Anbar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Biophotonics Inc
Original Assignee
Advanced Biophotonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biophotonics Inc filed Critical Advanced Biophotonics Inc
Publication of AU5788401A publication Critical patent/AU5788401A/en
Application granted granted Critical
Publication of AU750660B2 publication Critical patent/AU750660B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/01Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
    • A61B5/015By temperature mapping of body part
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00Image analysis
    • G06T7/0002Inspection of images, e.g. flaw detection
    • G06T7/0012Biomedical image inspection
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00Image analysis
    • G06T7/40Analysis of texture
    • G06T7/41Analysis of texture based on statistical description of texture
    • G06T7/42Analysis of texture based on statistical description of texture using transform domain methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/0045Devices for taking samples of body liquids
    • A61B2010/008Interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7253Details of waveform analysis characterised by using transforms
    • A61B5/7257Details of waveform analysis characterised by using transforms using Fourier transforms
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/10Image acquisition modality
    • G06T2207/10048Infrared image
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/20Special algorithmic details
    • G06T2207/20048Transform domain processing
    • G06T2207/20056Discrete and fast Fourier transform, [DFT, FFT]
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/30Subject of image; Context of image processing
    • G06T2207/30004Biomedical image processing
    • G06T2207/30088Skin; Dermal

Description

METHOD OF DETECTING CANCEROUS LESIONS BACKGROUND OF THE INVENTION The present invention relates generally to cancer detection and, more particularly, to a cancer detection method involving the measurement, recording and analysis of temporal periodic perfusion changes associated with dysfunction of neuronal control of the vasculature surrounding cancerous lesions. While the present invention has application to cancer detection throughout the human body, it is particularly applicable to a breast cancer screening test involving the measurement of temporal changes in perfusion over large areas of the breasts to identify cancer. Specifically, cancer detection is derived from a time series of infrared images of an area of interest of a human breast. The 20 infrared images relate to the temporal periodic perfusion changes and are converted by a computer to time series average temperature and standard deviation oo' of each of a plurality of subareas. The data is then analyzed to identify clusters having abnormal temperature dependent frequencies indicative of cancer.
SUMMARY OF THE INVENTION Thermoregulatory frequencies of the processes that control skin temperature over different areas of the 30 body are derived from the periodic changes in temperature distribution over those skin areas. As shown by Dr. Anbar in the European J Thermology 7:105- 118, 1997, under conditions of hyperperfusion, the o o.
WO 01/12067 PCT/US99/08853 2 homogeneity of the skin temperature distribution reaches a maximum and the amplitude of its temporal modulation is at a minimum. In other words, periodic changes in the spatial homogeneity of skin temperature (HST) are dictated by the processes that control the saturation of the cutaneous capillary bed in a particular area of the skin. Accordingly, skin temperature and HST are independent physiological hemodynamic parameters that are determined by the structure of the cutaneous vasculature and by its heat dissipatory activity.
However, unlike average temperature, HST is affected mainly by the behavior of the cutaneous capillaries and to a much lesser extent by the blood flow in subcutaneous vessels. As perfusion is enhanced, more capillaries are recruited as blood conduits and HST increases. The neuronal control of HST is, therefore, different from that of skin temperature. Consequently, the spatial distribution of changes in skin temperature and homogeneity, HST, of tissue derived from a time series of infrared images of a skin area according to the present invention is more informative than a classical thermogram. HST is the reciprocal of the spatial coefficient of variation of temperature in small ("micro") areas of skin 100 mm 2 HST average temperature divided by the standard deviation of the average temperature (HST is a dimensionless parameter) The concept of HST has been fully described by Dr.
Michael Anbar in Biomedical Thermology, 13:173-187, 1994.
These and other objects of the present invention will become increasingly more apparent to those skilled in the art by reference to the following description.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Although skin temperature may vary over a wide range, depending upon the environment and on the level of metabolic activity, it is regulated under normal WO 01/12067 PCT/US99/08853 3 conditions. This regulation may be occasionally less stringent, like during sleep but even then, some skin regulation is retained. In the human body, skin temperature maintenance is due, in substantial part to neuronal thermoregulation of vasoconstriction and vasodilation of the vasculature, thereby causing a characteristic modulation of blood perfusion, unless the neuronal thermoregulation is inhibited or taken over by a non-neuronal thermoregulatory control, such as nitric oxide Modulation of skin temperature is on the order of 10 to 50 millidegrees Kelvin.
NO has been recognized as an ubiquitous vasodilatory chemical messenger. Its main role appears to be synchronization of intercellular and inter organ functions, because it diffuses freely in the interstitial space. This has been discussed extensively by Dr. Anbar in J. Pain Symptom Management 14:225-254, 1997. Under certain conditions, such as in breast cancer, autocatalytic production of NO may occur, which results in oscillatory vasodilation, independent of and substantially different from the temperature oscillations of perfusion caused by the neuronal thermoregulatory system. NO can, therefore, inhibit autonomic vasoconstrictive control in substantial regions of the microvasculature and cause regional hyperperfusion. Subcutaneous and cutaneous hyperperfusion are manifested as hyperthermia of the overlying skin.
Thus, cancer associated breast hyperthermia results from impaired neuronal thermoregulation caused by excessive production of NO by breast cancer cells and in macrophages that react to the neoplastic tissue. The latter activity is an expression of the immune response because NO generated by macrophages is a major factor in killing of microorganisms or of mammalian cells recognized as alien. The mechanism for this activity is described fully in a 1994 publication of Dr. Michael WO 01/12067 PCTIUS99/08853 4 Anbar, Cancer Letters 84:23-29, 1994. The rate of production of NO is further enhanced by the presence of ferritin, the level of which is significantly elevated in breast cancerous tissue. Fe2 4 released from ferritin is used to produce more NO synthase (NOS), an iron carrying enzyme which produces NO from arginine, and thus results in a further increase in the rate of production of NO. Furthermore, NO has been shown to release Fe2' from ferritin by forming an NO-ferritin complex which consequently results in an autocatalytic production of NO. Fe2 also eliminates superoxide radicals
(HO
2 which are normally the major scavengers of NO. Elimination of HO2 maintains the local high level of NO, and hyperperfusion of the tissues surrounding the cancerous lesion. The ferritin dependent enhancement of NO production seems to be specific to neoplastic cells and is less likely to occur in other inflammatory situations, including those induced by microorganisms.
Therefore, the frequencies of temperature and HST oscillations observed over a cancerous breast differ substantially from those observed over a non-cancerous (normal) breast. The oscillations over a normal breast are caused by the neuronal thermoregulatory processes, which follow several characteristic bands of frequencies. The cancerous area of the breast, on the other hand, which loses its neuronal thermoregulatory control due to the over-production of NO, is characterized by the disappearance of the neuronal oscillations and the appearance of oscillations due to the autocatalysis of NO production, with their typical frequency bands. The latter autocatalytic processes, controlled by the temporary local depletion of one of the precursors of NO, are utterly different in nature from the neurological feedback processes manifested in the neuronal frequency bands. Consequently, the disappearance of neuronal frequencies over substantial WO 01/12067 PCT/US99/08853 5 parts of the cancerous breast is sufficient to identify pathology. Furthermore, the appearance of the autocatalytic frequencies characteristic of NO over-production is, by itself, sufficient to identify pathology. The substitution of one set of frequency bands by the other is an even more strict criterion of pathology in a human breast. Hemodynamic modulation is generally in the range of 0.8 to 2 Hz, whereas modulation by the autonomic nervous system ranges generally between 10 and 700 mHz.
It is the detection of these frequencies, whether neuronal or non-neuronal, which is the basis of the detection methods of the present invention.
Specifically, under conditions of extravascular NO overproduction and its consequent hyperperfusion, skin temperature and the homogeneity of skin temperature, HST, reach values that oscillate at frequencies dependent on the modulated autocatalytic rate of NO production. The frequency bands of the modulation of temperature and HST are, according to the present detection methods, independent criteria of pathology.
It should be understood that while the present detection methods are described herein with respect to a human breast, it is not intended to be so limited.
Detection of cancerous lesions in the hands, arms, chest, legs, buttocks, back and literally any other body part is possible with the present methods.
Thus, the screening techniques of the present invention use the spatial distribution of the characteristic oscillations or modulations in the temporal behavior of blood perfusion caused by enhanced NO production by cancerous cells and in macrophages and amplified by ferritin to detect an immune response induced by neoplastic disease. The temperature oscillation of blood perfusion associated with the autocatalytic production of NO, as well as the diminution or disappearance of the neuronal WO 01/12067 PCTIS99/08853 6 thermoregulatory frequencies, TRFs, are used as the diagnostic parameters. The neuronal and autocatalytic oscillations are measured by fast Fourier transform (FFT) analysis, an analysis method well known in the art, of the temporal behavior of breast perfusion (manifested in the temporal behavior of breast temperature and of HST). The TRFs of HST are, therefore, additional independent diagnostic parameters.
Accordingly, the present invention provides for the accumulation of hundreds of sequential thermal images that are then subjected to FFT to extract the frequencies and amplitudes of periodic changes at each pixel of the image. To measure the spatial distribution of modulation of temperature and HST, an infrared camera is positioned to provide infrared flux images of a part of the human body, for example a human breast. A preferred camera is equipped with a 256 x 256 focal plane array (FPA) GaAs quantum-well infrared photodetector (QWIP). Such a camera can record modulation of skin temperature and its homogeneity with a precision greater than 1 millidegrees C, less than 1/10 of physiological modulation of temperature and of homogeneity of human skin. Another camera that is useful with the present invention is a HgCdTi infrared photodetector.
While successful results can be achieved by analyzing the temporal behavior of at least 128 thermal images, it is most preferred to measure 1024 consecutive thermal images over a period of 10 to 60 seconds. The infrared images are transmitted to a CPU having an analog/digital converter which processes the recorded infrared flux information and outputs digital infrared flux data.
To determine whether the breast is normal or cancerous, the CPU factors the digital data to equivalent temperature readings for a designated spot subarea or group of spots of the breast (each spot WO 01/12067 PC'TIUS99/08853 7 subarea corresponds to about 25 to 100 mm 2 of skin based on a 256 x 256 pixel field, as will be described hereinafter), which are later to be analyzed for the presence of lesions. A spot is typically about four to sixteen pixels and can have the shape of a circle, square or other shapes. The temperature values of the pixels in each subarea of the image are averaged. The variance of the average temperature is used to calculate the HST of each subarea. The accumulated images are then analyzed by FFT to extract the corresponding frequencies of the average temperature and standard deviation of average temperature. The FFT yields the frequency spectra of each pixel together with the relative amplitude of each TRF. The software then tabulates, or displays as color-coded bitmaps, the spatial distribution of the TRFs within a given range of relative amplitudes over the image. The same procedure is followed with the HST data.
When TRFs in a cluster of subareas are displayed with amplitudes above a given threshold, a subset of characteristic neuronal frequencies over areas of breasts free from cancer-enhanced immune response is identified. A cluster is defined as at least six congruent subareas of four to sixteen pixels per subarea. Such TRFs are significantly attenuated or completely absent in areas overlying breasts with neoplastic lesions. The latter areas are characterized by non-neuronal thermoregulatory behavior which manifest substantially different TRFs caused by the autocatalytic production of NO. Also the latter areas are, therefore, characterized by aberrant modulation of blood perfusion and aberrant temperature oscillations. A hard copy in the form of a colored bitmap of the imaged skin area is then generated to allow an expert to anatomically identify the location of the aberrant area, or areas.
The computer algorithms that facilitate this computation are as follows: WO 01/12067 PCTIUS99/08853 8 A. Use of temperature values of individual pixels and the computation of TRFs.
1. The computerized camera takes an image of the infrared flux (256 x 256 pixels) of an area of interest of the skin, such as of a human breast, and converts it into a digital thermal image where each pixel has a certain temperature value. This process is repeated, preferably thirty times a second until 1024 thermal images have been accumulated and stored in the computer.
2. The infrared image is subdivided into subareas of 4 to 16 pixels, each subarea corresponding to about 25 to 100 square millimeters of skin, depending on the optics of the camera and the geometry of the measurement. For example, in a 256 x 256 pixel field, each pixel represents about 2.4 mm 2 Higher resolution camera will have greater skin area detail. The computer then converts each infrared image into a digital thermal image where each pixel has a certain temperature value.
3. The computer calculates the average temperature and the temperaturestandard deviation of each of the subareas in each of the 1024 images. The average temperature values of each subarea constitutes a single time series that is then subjected to FFT analysis to extract the contributing frequencies of each image of the series and their relative amplitudes. The computer stores the resulting FFT spectrum for the calculated subarea related to the subdivided area of the image. The computer repeats the same procedure for each of the subareas of the image of the skin. Additionally, or in the WO 01/12067 PCT/US99/08853 9 alternative, the temperature standard deviation value of each subarea can be used to calculate a time series that is subjected to FFT analysis to extract the contributing frequencies of each image of the series and their relative amplitudes.
4. The computer selects the FFT spectra of each of the subareas and displays colored bitmaps of the relative amplitudes derived from the FFT analysis in any exhibited range of frequencies to thereby identify clusters of subareas having frequencies with abnormal amplitudes.
If procedure #4 does not identify definitely aberrant clusters, the computer determines that the test is negative for cancer and the patient is normal. A message to this effect is then output by the computer. Otherwise, the computer proceeds with procedure #6.
6. The computer examines all the pixels in the aberrant clusters identified in procedure #4 to identify frequencies with amplitudes that are characteristic of cancer, at least six congruent subareas wherein a spatial distribution of the amplitude value in the congruent subareas is less than about 10%, and preferably less than about 20%, or more than 100% of the average amplitudes of the temperature values of all of the surrounding subareas.
7. If procedure #4 identifies a definitely aberrant cluster, while procedure #6 turns out negative, the computer prints out a color image of the breast. If procedure #6 yield a confirmation, the computer prints out another color image with the aberrant clusters.
WO 01/12067 PCT/US99/08853 10 B. Use of HST values and the computation of HST TRFs.
1. The computerized camera takes on image of the infrared flux (256 x 256 pixels) of an area of interest of the skin, such as a human breast, and converts it into a thermal image where each pixel has a certain temperature value.
This process is respected, preferably thirty times a second until 1024 thermal images have been accumulated and stored in the computer.
2. The infrared image is subdivided into subareas of 4 to 16 pixels, each subarea corresponding to about 25 to 100 square millimeters of skin, based on the 256 x 256 optics resolution of the camera. The computer then converts each infrared image into a digital thermal image where each pixel has a certain temperature value.
3. The computer calculates the average temperature (AVT) value and temperature standard deviation (SD) of each subarea. The computer then calculates the HST value for each subarea: HST AVT/SD. The HST values are analyzed by FFT to extract the contributing frequency of each subarea to yield HST TRFs, and the relative amplitude of each frequency.
4. The computer selects the FFT spectra of each of the subareas and displays colored bitmaps of the relative amplitude derived from the FFT analysis in any exhibited range of frequencies to thereby identify clusters of subareas with frequencies having abnormal amplitudes.
If procedure #4 does not identify definitely aberrant clusters, the computer determines that the test is negative for cancer and the patient is normal. A message to this effect WO 01/12067 PCTIUS99/08853 11 is then output by the computer. Otherwise, the computer proceeds with procedure #6.
6. The computer examines all the subareas in the aberrant clusters identified in procedure #4 to identify frequencies that are characteristic of cancer, at least six congruent subareas wherein a spatial distribution of the amplitude value in the congruent subareas is less than about 10%, and preferably less than about 20%, or more than 100% of the amplitudes of the HST values of all of the surrounding subareas.
7. If procedure #4 identifies a definitely aberrant cluster, while procedure #6 turns out negative, the computer prints out a color image of the breast. If procedure #6 yields a confirmation, the computer prints out another color image with the aberrant clusters.
8. A match between the findings of procedure A and B increases the diagnostic certainty of the detection method of the present invention.
According to a further aspect of the present invention, the difference between normal and cancerous breasts is accentuated by a thermal challenge (cooling or warming) of the breasts. Such a thermal challenge affects only the neuronal thermoregulatory system and therefore affects only TRFs in areas that are not vasodilated by excessive extravascular NO production.
The computer is programmed to look for the frequency bands of the neuronal and the NO controlled TRFs in every subset of pixels 4 to 16 pixels) of the FFT processed image. If the computer does not find any clusters with neuronal TRFs having exceptionally low amplitude (except in the periphery of the image which does not depict skin), and no clusters are found to have the NO controlled autocatalytic TRFs with a significant -12 amplitude, the findings of the test are declared as negative normal). This finding is then confirmed by computing and analyzing the HST TRFs. If the computer finds certain clusters with exceptionally low neuronal TRFs and especially if those clusters exhibit the NO controlled autocatalytic TRFs, the test findings are classified as pathological. This finding is then confirmed by analyzing the HST data, as described for the uncooled or unwarmed breast. Cooling or warming of the breasts (by a mild flow of forced air) attains maximal sensitivity and specificity. Such additional testing is administered as a confirmatory test only to patients who show a positive result on the uncooled test.
Although the invention has been described in detail for the purpose of illustration, it is to be understood that such detail is solely for that purpose and that variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention except as it may be limited by the claims.
As employed above and throughout this disclosure (including the claims), the following terms, unless otherwise indicated, shall be understood to have the following meanings: "comprises/comprising" when used in, this specification is taken to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or. more other features, integers, steps, components or groups thereof.

Claims (27)

  1. 2. The method of claim 1 including analyzing the average temperature value of each of the plurality of subareas to determine a contributing frequency of each average temperature value and displaying a presentation of the relative amplitude value of each frequency of the subareas, wherein when a spatial distribution of the amplitude of a given frequency of the cluster is less than about 25% or more than 100% of the average amplitude value of that frequency of the plurality of subareas, that cluster is determined to be cancerous. WO 01/12067 PCT/US99/08853 14
  2. 3. The method of claim 1 wherein when the spatial distribution of the average temperature amplitude of the cluster is less than about 10% of the average amplitude of the plurality of subareas, that cluster is determined to be cancerous.
  3. 4. The method of claim 1 wherein the infrared images are converted to corresponding digital thermal images.
  4. 5. The method of claim 1 including providing the infrared image of a field of 256 x 256 pixels.
  5. 6. The method of claim 1 including recording about 128 to 1024 thermal images.
  6. 7. The method of claim 6 wherein the thermal images are recorded consecutively.
  7. 8. The method of claim 6 including recording the thermal images in a period of about 10 to 60 seconds.
  8. 9. The method of claim 1 including subdividing the predetermined area of skin into the plurality of subareas of about 24 to 100 square millimeters of skin based on a 256 x 256 pixel field. The method of claim 1 including subdividing the predetermined area of skin into a plurality of subareas of about 4 to 16 pixels.
  9. 11. The method of claim 1 including analyzing the computed average temperature value of the selected subarea using a fast Fourier transform analysis.
  10. 12. The method of claim 1 including determining that the predetermined area of skin is of cancerous tissue. WO 01/12067 PCT/US99/08853 15
  11. 13. The method of claim 1 including determining that the predetermined area of skin is of non-cancerous tissue.
  12. 14. The method of claim 1 including determining that the predetermined area of skin includes both non- cancerous tissue and cancerous tissue. The method of claim 1 including recording the infrared images using either a HgCdTi or a GaAs quantum- well infrared photodetector.
  13. 16. The method of claim 1 including providing the presentation as a color-coded bitmap.
  14. 17. The method of claim 1 including subjecting the predetermined are of skin to either a cooling or warming air flow.
  15. 18. The method of claim 1 wherein the predetermined area of skin is a human breast.
  16. 19. A method of detecting cancerous tissue, comprising the steps of: a) recording a plurality of infrared images of a predetermined area of skin; b) converting each of the plurality of infrared images into corresponding thermal images; c) subdividing the predetermined area of skin into a plurality of subareas; d) calculating an average temperature value and a temperature standard deviation for the plurality of thermal images of each of the subareas; e) dividing the average temperature by the standard deviation of each of the subareas to derive a homogeneity of skin temperature (HST) value for each WO 01/12067 PCT/US99/08853 16 subarea, wherein the HST value for each subarea constitutes a time series for that subarea; and f) analyzing the HST value of the time series of each of the subareas, wherein when a spatial distribution of the HST value of a cluster comprising at least six congruent subareas is less than about 20% or more than 100% of the average HST value of the plurality of subareas, that cluster is determined to be cancerous.
  17. 20. The method of claim 19 including analyzing the HST value of each of the plurality of subareas to determine a contributing frequency of each HST value and displaying a presentation of the relative amplitude value of each frequency of the plurality of subareas, wherein when a spatial distribution of the amplitude of a given frequency of the cluster is less than about or more than 100% of the average HST value of the plurality of subareas, that cluster is determined to be cancerous.
  18. 21. The method of claim 19 wherein the infrared images are converted to corresponding digital thermal images.
  19. 22. The method of claim 19 including providing the infrared image of a field of 256 x 256 pixels.
  20. 23. The method of claim 19 including recording about 128 to 1024 thermal images.
  21. 24. The method of claim 23 including recording the thermal images in a period of about 10 to 60 seconds. The method of claim 19 including subdividing the predetermined area of skin into the plurality of subareas of about 24 to 100 square millimeters of skin based on a 256 x 256 pixel field. WO 01/12067 PCT/US99/08853 17
  22. 26. The method of claim 19 including subdividing the predetermined area of skin into a plurality of subareas of about 4 to 16 pixels.
  23. 27. The method of claim 19 including analyzing the computed average temperature value of the selected subarea using a fast Fourier transform analysis.
  24. 28. The method of claim 19 including providing the presentation as a color-coded bitmap.
  25. 29. The method of claim 19 including subjecting the predetermined area of skin to either a cooling or warming air flow. A method of detecting cancerous tissue, comprising the steps of: a) recording a plurality of infrared images of a predetermined area of skin; b) converting each of the plurality of infrared images into corresponding thermal images; c) subdividing the predetermined area of skin into a plurality of subareas; d) calculating an average temperature value and a temperature standard deviation for the plurality of thermal images of a selected one of the subareas, wherein the temperature standard deviation value for the selected subarea constitutes a time series for that subarea; e) repeating the procedure of steps a) to d) on the remaining subareas of the predetermined area of the skin; and f) analyzing the temperature standard deviation value of the time series of each of the subareas, wherein when a spatial distribution of the temperature standard deviation value of a cluster comprising at least six congruent subareas is less than about 20% or WO 01/1 2067 PCT/US99/08853 18 more than 100% of the temperature standard deviation of the plurality of subareas, that cluster is determined to be cancerous.
  26. 31. The method of claim 30 including analyzing the temperature standard deviation value of each of the plurality of subareas to determine a contributing frequency of each temperature standard deviation value and displaying a presentation of the relative amplitude value of each frequency of the subareas, wherein when a spatial distribution of the amplitude of a given frequency of the cluster is less than about 25% or more than 100% of the average amplitude value of that frequency of the plurality of subareas, that cluster is determined to be cancerous.
  27. 32. A method of detecting cancerous tissue, comprising the steps of: a) recording a plurality of infrared images of a predetermined area of skin; b) converting each of the plurality of infrared images into corresponding thermal images; c) subdividing the predetermined area of skin into a plurality of subareas; d) calculating an average temperature value and a temperature for the plurality of thermal images of a selected one of the subareas, wherein the average temperature standard deviation value for the selected subarea constitutes a time series for that subarea; e) repeating the procedure of steps a) to d) on the remaining subareas of the predetermined area of the skin; f) analyzing the average temperature value of the time series of each of the subareas, wherein when a spatial distribution of the average temperature value of a cluster comprising at least six congruent subareas is less than about 20% or more than 100% of the average WO 01/12067 PCT/U]S99/08853 19 temperature of the plurality of subareas, that cluster is determined to be cancerous, and if a cluster is determined to be cancerous; g) dividing the average temperature by the standard deviation of each of the subareas to derive a homogeneity of skin temperature (HST) value for each subarea, wherein the HST value for each subarea constitutes an HST time series for that subarea; and h) analyzing the HST value of the time series of each of the subareas, wherein when a spatial distribution of the HST value of a cluster comprising at least six congruent subareas is less than about 20% or more than 100% of the average HST value of the plurality of subareas, that cluster is determined to be cancerous.
AU57884/01A 1998-05-27 1999-04-22 Method of detecting cancerous lesions Ceased AU750660B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/085,627 US5961466A (en) 1995-01-03 1998-05-27 Method of detection of cancerous lesions by their effect on the spatial distribution of modulation of temperature and homogeneity of tissue
US09/085627 1998-05-27
PCT/US1999/008853 WO2001012067A1 (en) 1998-05-27 1999-04-22 Method of detecting cancerous lesions

Publications (2)

Publication Number Publication Date
AU5788401A AU5788401A (en) 2001-07-16
AU750660B2 true AU750660B2 (en) 2002-07-25

Family

ID=22192874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57884/01A Ceased AU750660B2 (en) 1998-05-27 1999-04-22 Method of detecting cancerous lesions

Country Status (8)

Country Link
US (1) US5961466A (en)
EP (1) EP1105042A4 (en)
JP (1) JP2003506188A (en)
AR (1) AR016031A1 (en)
AU (1) AU750660B2 (en)
BR (1) BR9910743A (en)
NZ (1) NZ508424A (en)
WO (1) WO2001012067A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610700D0 (en) * 1996-05-22 1996-07-31 Moor Instr Ltd Apparatus for imaging microvascular blood flow
US7280866B1 (en) 1999-10-06 2007-10-09 National Research Council Of Canada Non-invasive screening of skin diseases by visible/near-infrared spectroscopy
WO2001054580A1 (en) 2000-01-27 2001-08-02 National Research Council Of Canada Visible-near infrared spectroscopy in burn injury assessment
US8256430B2 (en) 2001-06-15 2012-09-04 Monteris Medical, Inc. Hyperthermia treatment and probe therefor
WO2002061858A2 (en) 2000-11-17 2002-08-08 Thermogenic Imaging, Inc. Apparatus and methods for infrared calorimetric measurements
US20020132360A1 (en) 2000-11-17 2002-09-19 Flir Systems Boston, Inc. Apparatus and methods for infrared calorimetric measurements
CN1527987A (en) * 2000-12-15 2004-09-08 全向磁带回线自动记录器技术公司 Method and apparatus for measuring physiology by means of infrared detector
US20050084086A1 (en) * 2002-02-15 2005-04-21 Hesse Thomas H. Systems and methods for conferencing among governed and external participants
AU2005234725B2 (en) 2003-05-22 2012-02-23 Evogene Ltd. Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby
US7554007B2 (en) * 2003-05-22 2009-06-30 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants
US7214195B2 (en) * 2003-07-23 2007-05-08 Lockheed Martin Corporation Method of and apparatus for detecting diseased tissue by sensing two bands of infrared radiation
EP1766058A4 (en) 2004-06-14 2008-05-21 Evogene Ltd Polynucleotides and polypeptides involved in plant fiber development and methods of using same
JP2006101900A (en) * 2004-09-30 2006-04-20 Mazda Motor Corp Medical image processing system
EP1831785A2 (en) * 2004-12-02 2007-09-12 3M Innovative Properties Company Network-based delivery of technical service to automotive manufacturers
JP5274248B2 (en) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Nitric oxide releasing particles for nitric oxide therapy and biomedical applications
EP2716654A1 (en) * 2005-10-24 2014-04-09 Evogene Ltd. Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
MX2009010858A (en) 2007-04-09 2009-11-02 Evogene Ltd Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants.
FR2916883B1 (en) * 2007-05-29 2009-09-04 Galderma Res & Dev METHOD AND DEVICE FOR ACQUIRING AND PROCESSING IMAGES FOR DETECTION OF EVOLUTIVE LESIONS
CN102037127A (en) 2007-07-24 2011-04-27 伊沃基因有限公司 Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
AU2008344935C1 (en) * 2007-12-27 2016-07-14 Evogene Ltd. Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009083974A1 (en) 2007-12-31 2009-07-09 Real Imaging Ltd. Method apparatus and system for analyzing thermal images
WO2009083973A1 (en) * 2007-12-31 2009-07-09 Real Imaging Ltd. System and method for registration of imaging data
WO2009118721A1 (en) 2008-03-28 2009-10-01 Real Imaging Ltd. Method apparatus and system for analyzing thermal images
CA3148194A1 (en) 2008-05-22 2009-11-26 Evogene Ltd. Isolated polynucleotides and peptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
BR122021014172B1 (en) 2008-08-18 2022-09-06 Evogene Ltd METHOD TO INCREASE NITROGEN USE EFFICIENCY, FERTILIZER USE EFFICIENCY, PRODUCTION, GROWTH RATE, VIGOR, BIOMASS AND/OR STRESS TOLERANCE FROM LACK OF NITROGEN OF A PLANT
US8185485B2 (en) * 2008-08-27 2012-05-22 Lifeline Biotechnologies, Inc. Device for analyzing thermal data based on breast surface temperature for the detection for use in determining cancerous conditions
US8226572B2 (en) * 2008-08-27 2012-07-24 Lifeline Biotechnologies, Inc. Methods for collecting and analyzing thermal data based on breast surface temperature to determine suspect conditions
US8231542B2 (en) * 2008-08-27 2012-07-31 Lifeline Biotechnologies, Inc. System for analyzing thermal data based on breast surface temperature to determine suspect conditions
US20110230942A1 (en) * 2008-12-01 2011-09-22 The Johns Hopkins University High-resolution infrared imaging for enhanced detection, diagnosis, and treatment of cutaneous lesions
WO2010064249A1 (en) 2008-12-04 2010-06-10 Real Imaging Ltd. Method apparatus and system for determining a thermal signature
EP3862433A3 (en) 2009-03-02 2021-11-17 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
BR112012003804B1 (en) 2009-08-21 2019-02-19 Novan, Inc. Wound Dressing, Method to Form an Injury Dressing, and Wound Dressing Kit
EP2467127B1 (en) 2009-08-21 2023-08-02 Novan, Inc. Topical gels
US20130023773A1 (en) * 2010-04-07 2013-01-24 Stc. Unm Apparatus and techniques of non-invasive analysis
EP2627242B1 (en) * 2010-10-14 2019-12-04 Performance In Cold AB Method and device for examining the surface temperature of a body part
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
CN104602638B (en) 2012-06-27 2017-12-19 曼特瑞斯医药有限责任公司 System for influenceing to treat tissue
PT3117777T (en) 2014-03-12 2020-06-17 Integral Geometry Science Inc Scattering tomography method and scattering tomography device
US9486170B2 (en) 2014-03-18 2016-11-08 Monteris Medical Corporation Image-guided therapy of a tissue
US10675113B2 (en) 2014-03-18 2020-06-09 Monteris Medical Corporation Automated therapy of a three-dimensional tissue region
US20150265353A1 (en) 2014-03-18 2015-09-24 Monteris Medical Corporation Image-guided therapy of a tissue
KR101642299B1 (en) * 2014-08-07 2016-07-25 박영훈 Diagnosis system and method of breast cancer
US10327830B2 (en) 2015-04-01 2019-06-25 Monteris Medical Corporation Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor
CA3101189A1 (en) * 2018-06-13 2019-12-19 Bired Imaging Inc. Detection and characterization of cancerous tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366381A (en) * 1979-12-14 1982-12-28 Agfa-Gevaert Aktiengesellschaft Electrothermographic apparatus for detection and pinpointing of malignancies in human bodies
US4428382A (en) * 1980-09-03 1984-01-31 Gst Laboratories, Inc. Method for identifying the presence of abnormal tissue
US5678555A (en) * 1996-04-08 1997-10-21 O'connell; Peter Method of locating and marking veins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4445516A (en) * 1980-05-29 1984-05-01 Carl Zeiss-Stiftung Process for the digitization and display of thermographic records
FR2604524B1 (en) * 1986-09-26 1989-10-13 Thomson Cgr METHOD FOR MEASURING PARAMETERS OF MOLECULAR DIFFUSION AND / OR PERFUSION OF A LIVING TISSUE SUBJECT TO NUCLEAR MAGNETIC RESONANCE EXPERIMENTATION
GB8907101D0 (en) * 1989-03-29 1989-05-10 Nat Res Dev Blood flow determination
US5207227A (en) * 1990-03-02 1993-05-04 Powers Alexandros D Multiprobes with thermal diffusion flow monitor
JPH0449949A (en) * 1990-06-15 1992-02-19 Hitachi Ltd Magnetic resonance thermography
US5845639A (en) * 1990-08-10 1998-12-08 Board Of Regents Of The University Of Washington Optical imaging methods
US5233994A (en) * 1991-05-13 1993-08-10 Advanced Technology Laboratories, Inc. Detection of tissue abnormality through blood perfusion differentiation
US5205293A (en) * 1991-10-30 1993-04-27 Koichi Sakurai Method of measuring surface blood flow
JPH05228098A (en) * 1992-02-20 1993-09-07 Asahi Optical Co Ltd Thermoendoscope
US5810010A (en) * 1995-01-03 1998-09-22 Anbar; Michael Detection of cancerous lesions by their effect on the periodic modulation of perfusion in the surrounding tissues
US5771261A (en) * 1995-09-13 1998-06-23 Anbar; Michael Telethermometric psychological evaluation by monitoring of changes in skin perfusion induced by the autonomic nervous system
GB9606124D0 (en) * 1996-03-22 1996-05-22 Rogers Gary System for detecting cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366381A (en) * 1979-12-14 1982-12-28 Agfa-Gevaert Aktiengesellschaft Electrothermographic apparatus for detection and pinpointing of malignancies in human bodies
US4428382A (en) * 1980-09-03 1984-01-31 Gst Laboratories, Inc. Method for identifying the presence of abnormal tissue
US5678555A (en) * 1996-04-08 1997-10-21 O'connell; Peter Method of locating and marking veins

Also Published As

Publication number Publication date
WO2001012067A8 (en) 2001-09-07
EP1105042A1 (en) 2001-06-13
AU5788401A (en) 2001-07-16
WO2001012067A1 (en) 2001-02-22
BR9910743A (en) 2002-04-23
JP2003506188A (en) 2003-02-18
US5961466A (en) 1999-10-05
NZ508424A (en) 2002-11-26
AR016031A1 (en) 2001-05-30
EP1105042A4 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
AU750660B2 (en) Method of detecting cancerous lesions
AU737901B2 (en) Detection of cancerous lesions by their effect on the spatial homogeneity of skin temperature
US5810010A (en) Detection of cancerous lesions by their effect on the periodic modulation of perfusion in the surrounding tissues
US7485098B2 (en) Method of and apparatus for detecting diseased tissue by sensing two bands of infrared radiation
Woldorff et al. Magnetoencephalographic recordings demonstrate attentional modulation of mismatch-related neural activity in human auditory cortex
Katayama et al. Stimulus context determines P3a and P3b
Ruchkin et al. Multiple visuospatial working memory buffers: Evidence from spatiotemporal patterns of brain activity
US20040076316A1 (en) Method and apparatus for measuring physiology by means of infrared detector
Strüber et al. P300 and slow wave from oddball and single-stimulus visual tasks: inter-stimulus interval effects
Nakamura et al. Effects of check size on pattern reversal visual evoked magnetic field and potential
Oken et al. Computerized EEG frequency analysis: sensitivity and specificity in patients with focal lesions
Vaquero et al. Gender differences in event-related potentials during visual-spatial attention
JP2017063997A (en) Biological function examination device, biological function examination method and program
CA2333406A1 (en) Method of detecting cancerous lesions
Lara et al. Electroencephalographic and skin temperature indices of vigilance and inhibitory control
Behzadnia et al. The neural correlation of sustained attention in performing conjunctive continuous performance task: an event-related potential study
MXPA00010253A (en) Detection of cancerous lesions by their effect on the spatial homogeneity of skin temperature
Schwartz et al. Alpha suppression related to a cognitive task
Gush et al. Laser Doppler imaging of blood perfusion in tissue: from research to clinical applications
Petrova et al. Dynamic Mapping of the Temperature Fields of the Brain
Scully et al. QIRT 10

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)